Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Amortizatization of Intangibles: 2018-2024

Historic Amortizatization of Intangibles for Crinetics Pharmaceuticals (CRNX) over the last 7 years, with Dec 2024 value amounting to $14.9 million.

  • Crinetics Pharmaceuticals' Amortizatization of Intangibles rose 2.50% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.9 million, marking a year-over-year increase of 17.43%. This contributed to the annual value of $14.9 million for FY2024, which is 138.10% up from last year.
  • According to the latest figures from FY2024, Crinetics Pharmaceuticals' Amortizatization of Intangibles is $14.9 million, which was up 138.10% from $6.3 million recorded in FY2023.
  • In the past 5 years, Crinetics Pharmaceuticals' Amortizatization of Intangibles registered a high of $14.9 million during FY2024, and its lowest value of -$422,000 during FY2021.
  • For the 3-year period, Crinetics Pharmaceuticals' Amortizatization of Intangibles averaged around $7.1 million, with its median value being $6.3 million (2023).
  • In the last 5 years, Crinetics Pharmaceuticals' Amortizatization of Intangibles plummeted by 285.90% in 2021 and then skyrocketed by 18,544.12% in 2023.
  • Crinetics Pharmaceuticals' Amortizatization of Intangibles (Yearly) stood at $227,000 in 2020, then plummeted by 285.90% to -$422,000 in 2021, then spiked by 91.94% to -$34,000 in 2022, then soared by 18,544.12% to $6.3 million in 2023, then spiked by 138.10% to $14.9 million in 2024.